# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Jefferies analyst Maury Raycroft initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Buy rating and announces Pric...
Cantor Fitzgerald analyst Eric Schmidt reiterates Tango Therapeutics (NASDAQ:TNGX) with a Overweight.
HC Wainwright & Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:TNGX) with a Buy and maintains $13 price ...
HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and lowers the price targ...
Guggenheim analyst Charles Zhu maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and lowers the price target from $16 to...
Barclays analyst Peter Lawson maintains Tango Therapeutics (NASDAQ:TNGX) with a Overweight and lowers the price target from ...